This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2003 Aug 12;61(3):286-7.

doi: 10.1212/wnl.61.3.286.

Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off?

PMID: 12913183
DOI: 10.1212/wnl.61.3.286

Editorial

Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off?

Andrew Feigin. Neurology. 2003.

. 2003 Aug 12;61(3):286-7.

doi: 10.1212/wnl.61.3.286.

Author

PMID: 12913183
DOI: 10.1212/wnl.61.3.286

No abstract available

PubMed Disclaimer

Comment on

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.
Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, Morris MJ, Mouradian MM, Chase TN. Bara-Jimenez W, et al. Neurology. 2003 Aug 12;61(3):293-6. doi: 10.1212/01.wnl.0000073136.00548.d4. Neurology. 2003. PMID: 12913186 Clinical Trial.
Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.
Hauser RA, Hubble JP, Truong DD; Istradefylline US-001 Study Group. Hauser RA, et al. Neurology. 2003 Aug 12;61(3):297-303. doi: 10.1212/01.wnl.0000081227.84197.0b. Neurology. 2003. PMID: 12913187 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information